-
2 weeks ago | 
oncologynewscentral.com | Neil Osterweil
Some patients with early-stage mismatch repair deficient (dMMR) tumors could be safely spared from upfront surgery, chemotherapy, or radiation with a six-month course of an immune checkpoint inhibitor targeted to PD-1, data from a phase 2 trial suggest. Results of the study were reported at the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago and published online in The New England Journal of Medicine.
-
2 weeks ago | 
oncologynewscentral.com | Neil Osterweil
Tumors that harbor mutations or deficiencies in DNA repair pathways may respond to the combination of a poly (ADP-ribose) polymerase (PARP) inhibitor and immune checkpoint inhibitor, with tumors positive for BRCA1/2mutations especially vulnerable, suggest results of the tumor-agnostic phase 2 KEYLYNK-007 trial.
-
2 weeks ago | 
oncologynewscentral.com | Neil Osterweil
A regimen combining two immune checkpoint inhibitors that showed potential efficacy in treating PD-L1–high locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) in a randomized phase 2 trial missed its dual primary endpoints of progression-free survival (PFS) and overall survival (OS) in the phase 3 SKYSCRAPER-01 trial.
-
2 weeks ago | 
oncologynewscentral.com | Neil Osterweil
Zongertinib, an investigational tyrosine kinase inhibitor (TKI) designed to be highly selective for HER2 while sparing wild-type EGFR, was associated with a high objective response rate (ORR), a low incidence of grade 3 or higher toxicities, and no reported cases of drug-related interstitial lung disease in a trial of patients with HER2-mutated non-small cell lung cancer (NSCLC).
-
2 weeks ago | 
medicalnewsinsider.substack.com | Neil Osterweil
High blood pressure is the leading modifiable risk factor for heart attack and stroke, and as new evidence from a study conducted in rural China suggests, it may also contribute to increased risk of dementia. Fortunately, as the study, published in the journal Nature Medicine, also shows, controlling high blood pressure (hypertension, in medical parlance) can significantly reduce the risk for dementia.
-
2 weeks ago | 
oncologynewscentral.com | Neil Osterweil
Adding the immune checkpoint inhibitor pembrolizumab (Keytruda) to the standard of care both before and after surgery resulted in significantly improved event-free survival (EFS) for patients with resectable, locally advanced head and neck squamous cell carcinomas (LA-HNSCC), results of the KEYNOTE-689 trial show.
-
4 weeks ago | 
oncologynewscentral.com | Neil Osterweil
The theme for the 2025 American Association for Cancer Research (AACR) Annual Meeting, to be held at the McCormick Place Convention Center in Chicago April 25–30, is “Unifying Cancer Science and Medicine: A Continuum of Innovation for Impact.”Program Committee Chairs Lillian L.
-
1 month ago | 
medicalnewsinsider.substack.com | Neil Osterweil
Imagine if your car could fix itself while you’re driving it—sealing oil leaks, tightening drive belts, re-inflating tires—all occurring as you zip along at highway speeds, oblivious to the continuous repair process. DNA does just that for human cells, activating nearly 550 genes that produce proteins to zoom in and repair anywhere from around 10,000 to 1,000,000 molecular lesions (think of them as DNA bruises) that occur in .
-
1 month ago | 
oncologynewscentral.com | Neil Osterweil
For patients with unresectable EGFR-mutated non-small cell lung cancer (NSCLC) who do not have disease progression after definitive chemoradiotherapy (CRT), maintenance therapy with osimertinib (Tagrisso) significantly delays the time to first subsequent therapy and shows favorable but not statistically significant survival trends, according to an updated analysis from the LAURA trial. Suresh S.
-
1 month ago | 
oncologynewscentral.com | Neil Osterweil
KRAS mutations occur in as many as 30% of non-small cell lung cancers (NSCLC) and were once considered “undruggable.” However, updated results from the phase 2 KROCUS trial suggest that a first-line combination consisting of the investigational KRAS G12c inhibitor fulzerasib (Dupert) plus the EGFR-targeting antibody cetuximab (Erbitux) is associated with a high and durable objective response rate (ORR) and is well-tolerated.
